Litigations for Unexpected Adverse Events

  • I. W. FongEmail author
Part of the Emerging Infectious Diseases of the 21st Century book series (EIDC)


A 53-year-old Iranian female who immigrated to Canada about 3.5 years before was referred to an internist for a positive Mantoux skin test (11 mm in diameter). The subject was previously well with no symptoms indicative or suggestive of active tuberculosis. A routine tuberculosis skin test was performed because the patient had applied to be a volunteer at a local hospital. She had no significant past illness or known allergies, and she was never diagnosed with nor had known contact with anyone with active tuberculosis. The subject never ingested alcohol and was not known to have hepatitis or be a carrier of any hepatitis virus. Baseline investigations performed by the internist included routine complete blood count, routine biochemical tests (liver enzymes, creatinine, and glucose), serum ferritin, and thyroid-stimulating hormone – all of which were normal. A chest radiograph was reported to be normal.


Herpes Zoster Varicella Zoster Virus Active Tuberculosis Toxic Epidermal Necrolysis Fulminant Hepatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    McEvoy GK, Miller J, Kesler L, Welsch OH (eds), (2009). Isoniazid. In: AHFS Drug Information. Am Soc Health Syst Pharmacists, Bethesda, p. 580–585.Google Scholar
  2. 2.
    Geng E, Kreiswirth B, Driver C, Li J, Burzynski J, Della Latta P, La Pas A, Schluger NW, (2002). Changes in the transmission of tuberculosis in the New York City from 1990 to 1999. N Engl J Med 346:1453–1458.PubMedCrossRefGoogle Scholar
  3. 3.
    Martinez-Lirola M, Alonso-Rodriguez N, Sanchez ML, Herranz M, Andries S, Penafiel T, Rogado ML, Cabezas T, Martinez J, Lucerna MA, Rodriguez M, Bonillo MDC, Bouza E, de Viedma DG, (2008). Advanced survey of tuberculosis transmission in a complex socioepidemiologic scenario with a high proportion of cases in immigrants. Clin Infect Dis 47:8–14.PubMedCrossRefGoogle Scholar
  4. 4.
    Centers for Disease Control and Prevention, (2007). Trends in tuberculosis incidence – United States 2006. MMWR Morb Mortal Rep 56:245–250.Google Scholar
  5. 5.
    World Health Organization, (2006). The global plan to stop TB 2006–2015. World Health Organization, Geneva, Switzerland.Google Scholar
  6. 6.
    World Health Organization, (2009). Global tuberculosis control: epidemiology strategy, financing. World Health Organization Report, Geneva, Switzerland.Google Scholar
  7. 7.
    Ramkumar D, La Brecque DR, (2003). Drug-induced liver disease and environmental toxins. In: (eds) Zakin D, Boyer TD; Hepatology: a textbook of liver disease; 4th Edition, Saunders, Philadelphia, p. 755–838.Google Scholar
  8. 8.
    Altman C, Biour M, Grange J, (1993). Hepatic toxicity of antitubercular agents. Role of different drugs, 199 cases. Press Med 22:1212.PubMedGoogle Scholar
  9. 9.
    Dickinson, D, Bailey WC, Hinoschowitz BI, Soony SJ, Leslie MD, Hodgkin MM, (1981). Risk factor for isoniazid (INH)-induced liver dysfunction. J Clin Gastroenterol 3:271–279.PubMedCrossRefGoogle Scholar
  10. 10.
    Raviglione MC, O’Brien RJ, (2008). Tuberculosis. In: (eds) Fauci AS, Braunwald E, Kasper DC, Hauser SC, Longo DC, Jameson JC, Loscalzo J. Harrison’s Principles of Internal Medicine, 17th Edition, McGraw-Hill, New York, p. 1006–1020.Google Scholar
  11. 11.
    Canadian Pharmacists Association, (2009). Isoniazid. In: CPS 2009: Compendium of Pharmaceuticals and Specialties. Can Pharm Assoc, Ottawa, p. 1187–1190.Google Scholar
  12. 12.
    Tostmann A, Boeree MJ, Aanoutse RE, de Lange WL, van der Ven AJ, Dekhuijen R, (2008). Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 23:192–2002.PubMedCrossRefGoogle Scholar
  13. 13.
    Fong IW (ed.), (2009), Emergency issues in head and neck infections. IN: Emerging issues and controversies in infectious disease; Springer, New York, p. 27–46.Google Scholar
  14. 14.
    International Rhinosinusitis Advisory Board, (1992). Infectious rhinosinusitis in adults: classification, etiology and management. Ear Nose Throat J. 76 (72):1–19.Google Scholar
  15. 15.
    Finegold SM, Flyan MJ, Rose FK, Jousimies-Somer H, Jukielaszek C, McTeague M, Wexler HM, Bekowitz E, Wynne B, (2002). Bacteriologic finding associated with chronic bacterial maxillary sinusitis in adults. Clin Infect Dis 35:428–433.PubMedCrossRefGoogle Scholar
  16. 16.
    Lawson DH, Price BJ, (1982). Adverse reactions to trimethoprim-sulfamethoxazole. Rev Infect Dis 4:429–433.PubMedCrossRefGoogle Scholar
  17. 17.
    Valeyrie-Allanore L, Roujeau JC, (2008). Epidermal necrolysis (Stevens-Johnson Syndrome and toxic epidermal necrolysis). In: (eds) Wolff K, Goldsmith LA, Kutz SI, Gilchrist BA, Paller AS, Leffell DJ: Fitzpatrick’s Dermatology in General Medicine, 7th Edition; McGrawHill, New York, p. 349–355Google Scholar
  18. 18.
    Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, Mockenhaupt M, Paoletti E, Shapiro S, Shear N, Schöpf E, Kaufman DW, (1995), Medication use and the risk of Stevens-Johnson Syndrome or toxic epidermal necrolysis. N Engl J Med 333:1600–1608.PubMedCrossRefGoogle Scholar
  19. 19.
    Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau J-C, Revuz J, Wolkenstein P, (2000). SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 115:149–153.PubMedCrossRefGoogle Scholar
  20. 20.
    Guégan S, Bastuji-Garin S, Poszepczynska-Guigne E, Roujeau JC, Revuz J (2006). Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Derm 126:272–276.PubMedCrossRefGoogle Scholar
  21. 21.
    Brown KM, Silver GM, Halerz M, Walaszek, Sandroni A, Gamelli RL (2004). Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 25:81–88.PubMedCrossRefGoogle Scholar
  22. 22.
    Bachot N, Revuz J, Roujeau JC (2003). Intravenous immunoglobulin treatment for Steven-Johnson syndrome and toxic epidermal necrolysis: prospective non-comparative study showing no benefit in mortality or progression. Arch Dermatol 139:33–36.PubMedCrossRefGoogle Scholar
  23. 23.
    Berris K (2009). Adverse events – physician-prescried opioids. Risk identification for all physicians. April 2009; Ri0915E. CMPA website:
  24. 24.
    Straus SE, Oxman MN, Schmader KE (2008). Varicella and Herpes Zoster. IN (eds): Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paker AS, Leffell DJ: Fitzpatrick’s Dermatology in General Medicine, 7th Edition, McGraw-Hill Medical, New York, p. 1885–1898.Google Scholar
  25. 25.
    Choo PW, Donahue JG, Manson JE, Platt R, (1995). The epidemiology of varicella and its complications. J Infect Dis 172:706–712.PubMedCrossRefGoogle Scholar
  26. 26.
    Preblud SR (1986). Varicella complications and cost. Pediatrics; 78 (suppl): S728–S735.Google Scholar
  27. 27.
    Feldman S, Hughes WT, Daniel CB (1975). Varicella in children with cancer.: seventy seven cases. Pediatrics; 56:388–397.PubMedGoogle Scholar
  28. 28.
    Locksley RM, Flournay N, Sullivan KM, Myers JD (1985). Infection with varicella zoster virus after marrow transplantation. J Infect Dis 152:1172–1181.PubMedCrossRefGoogle Scholar
  29. 29.
    Weller TH (1983). Varicella and herpes zoster: changing concepts of the natural history, control and importance of a not-so-benign virus (first of two parts). N Engl J Med 309:1362–1368.PubMedCrossRefGoogle Scholar
  30. 30.
    Frey FJ, Speck RF (1992). Glucocorticoids and infection. Schweiz-Med-Wochenschr 122:137–144.PubMedGoogle Scholar
  31. 31.
    Arcuri LB, Cashman LD, Cassaro AT, Kostick JH, Hsiung JRS, Wolfe KR (2009). Hormones and synthetic substitutes: adrenals. In AHFS Drug Information Am Soc Health Sys Pharmacists. Bethesda, MD, p. 3036–3128.Google Scholar
  32. 32.
    Balow JE, Hurley DL, Fauci AS (1975). Immunosuppressive effects of glucocorticosteroids: differential effects of acute vs chronic administration on cell-mediated immunity. J Immunol 114:1072–1076.PubMedGoogle Scholar
  33. 33.
    Schimmer BP, Parker KL (2005). Adrenocorticotropic hormone, adrenocortical steroids and their synthetic analogs: inhibitors of synthesis and actions of adrenocortical hormones. IN: (eds) Brunton LL, Lazo JS, Parker KL: Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 11th Edition, McGraw Hill, New York, p.1587–1612Google Scholar
  34. 34.
    Weller TH (1983). Varicella and herpes zoster: changes in concepts of natural history, control and importance of a not-so-benign virus (second of two parts). N Engl J Med 309:1434–1440.PubMedCrossRefGoogle Scholar
  35. 35.
    Zaia JA (1981). Clinical spectrum of varicella-zoster virus infection. IN: (eds) Nahmlas AJ, Dowdle WR, Schinazi RE: The human herpesviruses: an interdisciplinary perspective; Elsevier, p. 10–19.Google Scholar
  36. 36.
    Miliauskas JR, Webber BL (1984). Disseminated varicella at autopsy in children with cancer. Cancer 53:1518–1525.PubMedCrossRefGoogle Scholar
  37. 37.
    Patti ME, Selvaggi KJ, Kroboth FJ (1990). Varicella hepatitis in the immunocompromised adult: a case report and review of the literature. Am J Med 88:77–80.PubMedCrossRefGoogle Scholar
  38. 38.
    Sherman RA, Silva J Jr. Gandour-Edwards R (1991). Fatal varicella in an adult: case report and review of gastrointestinal complications of chickenpox. Rev Infect Dis 13:424–427.PubMedCrossRefGoogle Scholar
  39. 39.
    Maillot C, Riachi G, Francois A, Ducrotte P, Lerebours E, Hemet J, Colin R (1997). Digestive manifestations in an immunocompetent adult with varicella. Am J Gastroenterol 92:1361–1363.PubMedGoogle Scholar
  40. 40.
    Johnson HN (1940). Visceral lesions associated with varicella. Arch Pathol 30:292–307, 13.Google Scholar
  41. 41.
    Marshak RH, Lindwern AE (eds), (1976), in: Radiology of the small intestine; Saunders, Philadelphia, p. 487–496.Google Scholar
  42. 42.
    Bardhan KD (1978). Cimetidine in “chickenpox esophagitis”. BMJ 1:370 (letter).Google Scholar
  43. 43.
    Gill RA, Gebhard RL, Dozeman RL, Summer HW (1984). Shingles esophagitis: endoscopic diagnosis in two patients. Gastrointestin Endosc 30:26–27.CrossRefGoogle Scholar
  44. 44.
    Wallace MR, Bowler WA, Murray NB, Brodine SK, Oldfield III EC (1992). Treatment of adult varicella with acyclovir. A randomized placebo-controlled trial. Ann Intern Med 117:358–363.PubMedGoogle Scholar
  45. 45.
    Balfour HH, Bean H, Laskin OL, Ambinder RF, Myers JD, Wade JC, Zaia JA, Aeppli D, Segreti AC, Keeney RF (1983). Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 308:1448–1453.PubMedCrossRefGoogle Scholar
  46. 46.
    Shepp DH, Dandliker PS, Meyers JD (1986). Treatment of varicella-zoster virus infections in severely immunocompromised patients. N Engl J Med 314:208–212.PubMedCrossRefGoogle Scholar
  47. 47.
    Haake DA, Zakowski PC, Haake DL, Bryson YJ (1990). Early treatment with acyclovir for varicella pneumonia in otherwise healthy adults: retrospective controlled study and review. Rev Infect Dis 12:788–797.PubMedCrossRefGoogle Scholar
  48. 48.
    Escalante P (2009). In the clinic: tuberculosis. Ann Intern Med 150: ITC 6-1-14.Google Scholar
  49. 49.
    Oxman MN, Levin MJ, Johnson GR, Schmader KE, Strauss SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, et al, for the Shingles Prevention Study Group (2005). A vaccine to prevent herpes zoster and postherpetic neuralgia in older patients. N Engl J Med 352 V:2271–2284.CrossRefGoogle Scholar
  50. 50.
    Yeung CY, Liang DC (1992). Varicella vaccine in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Pediatr Hematol Oncol 9:29–34.PubMedCrossRefGoogle Scholar
  51. 51.
    Kroger AT, Atkinson WL, Marcuse EK, Pickering LK (2006). General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR:53(RR15);1–48.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.St. Michael’s HospitalUniversity of TorontoTorontoCanada

Personalised recommendations